Recurrent UTIs could be a sign of VUR, Deflux® treatment may help

Deflux is a minimally invasive treatment that has been proven effective in up to 93% of children, with no fUTIs after one injection.

Kalisvaart JF. Intermediate to long-term follow-up indicates low risk of recurrence after double hit endoscopic treatment for primary vesicoureteral reflux. J Ped Urol. 2012;8(4):359-365.



    A product by Palette Life Sciences

     Deflux is a gel made from two tissue-friendly polysaccharides (types of sugars) – hyaluronic acid (HA) and dextranomer (Dx) – and is used as a tissue bulking agent that is injected around the ureteral opening to prevent urine from flowing back up from the bladder through the ureters.

    The hyaluronic acid (HA) is naturally broken down (biodegraded) over a short time and replaced by the body’s own material, while the dextranomer remains in place longer. The HA in Deflux is Non-Animal Stabilized Hyaluronic Acid (NASHA®), a patented HA technology that is made from non-animal bacteria and crosslinked specifically for optimal stabilization. NASHA has been used safely for VUR for over two decades and has been used in more than 40 million procedures worldwide, often as a dermal filler.1

    A 2019 long-term follow-up study found that 94% of parents were highly satisfied with Deflux treatment.2 Additionally, in a survey of 91 families, 60% of parents preferred treatment with Deflux if they knew prolonged antibiotic therapy had to continue for 3-5 years or when operative treatment was required.3

    Deflux endoscopic treatment is indicated for reflux grades 2-4.


    1. Data on file.
    2. Lightfoot MA, Bilgutay AN, Tollin N, et al. Long-term clinical outcomes and parental satisfaction after dextranomer/hyaluronic acid injection for primary vesicoureteral reflux. Front Pediatr. 2019;7:392.
    3. Ogan K, Pohl HG, Carlson D, Belman AB, Rushton HG. Parental preferences in the management of vesicoureteral reflux. J Urol. 2001;166(1):240-243.
    4. Stenbäck A, Olafsdottir T, Sköldenberg E, et al. Proprietary non-animal hyaluronic acid/dextranomer gel (NASHA/Dx) for endoscopic treatment of grade IV vesicoureteral reflux: long-term observational study. J Ped Urol. 2020.
    Long-term study results

    A recent long-term study for grade 4 VUR patients showed Deflux treatment to be durable and effective at 15-25 years of follow-up. The same study showed that there was a low risk for UTIs, persistent VUR or need for open surgery.4